Quinoline Market Outlook:
Quinoline Market size was valued at USD 395.37 billion in 2025 and is expected to reach USD 602.35 billion by 2035, registering around 4.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of quinoline is evaluated at USD 410.67 billion.
The growth of the market is attributed to the rising usage of quinoline drug synthesis across the world. Quinoline-derivative drugs such as chloroquine, quinine, mefloquine, moxifloxacin, levofloxacin, gatifloxacin, and ofloxacin are used in the treatment of malaria and tuberculosis in the healthcare sector. Based on a study conducted by the Centers for Disease Control and Prevention (CDC) in 2021 with the CDC’s Tuberculosis Trails Consortium and the National Institutes of Health which is sponsored by AIDS Clinical Trails Group declared the results of a 4-month regimen from a randomized controlled trial. The 4-month regimen containing was found effective for the treatment of tuberculosis in patients above 12 years of age. The regimen comprises of with rifapentine, moxifloxacin, isoniazid, and pyrazinamide.
The increasing prevalence of malaria among people owing to a lack of proper awareness and a hygienic environment is estimated to propel quinoline market growth. The worldwide cases of malaria reached over 240 million in the year 2021 increased from 230 million in 2019 as per the estimations.
